Articles
Pharma news highlights: July

Pharma news highlights: July

This month’s news highlights, by Ed Silverman, include Pfizer and J&J’s cancellation of their Alzheimer’s drug studies and controversy following a vote by a California county in favour of drug makers disposing of expired prescription drugs. For the past several months, K-V Pharmaceutical regularly signalled that its ability to continue as a going concern is jeopardized...

Articles
Digital media: It’s time Indian pharma wakes up and smells the coffee

Digital media: It’s time Indian pharma wakes up and smells t...

Jini Mathai shares his thoughts on digital usage within the Indian pharmaceutical industry, looking at statistics around physicians’ use of social media and medical devices. Pharma brand building in India is becoming more challenging, with the time for a rep call shrinking to as...

Articles
Pharma gets social: what will Boehringer Ingelheim’s Syrum game achieve?

Pharma gets social: what will Boehringer Ingelheim’s Syrum g...

Daniel Ghinn discusses the possible positive outcomes to Boehringer Ingelheim’s Syrum, the highly-anticipated pharmaceutical social game, ahead of its launch this week. Ever since Boehringer Ingelheim first announced its imminent social media game via its Facebook page last summer, there has been growing anticipation...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. ESMO26: Tango sees 82% ORR with combo in pancreatic cancer
  2. Roche offers $15bn for strategic-level deal with Hansoh
  3. ESMO26: Moderna, MSD reveal cancer jab data early after leak
  4. Clinical trial setup times fall sharply in UK
  5. Despite US policy changes, drug prices stay stubbornly high

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more